Cancer Immunotherapy Sees Setback With Failure Of Cell Genesys’ GVAX
This article was originally published in The Pink Sheet Daily
Executive Summary
Cell Genesys will cut 75 percent of its workforce and explore strategic alternatives after halting development of the prostate cancer vaccine.
You may also be interested in...
Roche’s Push In Cancer Immunotherapy: An Interview With New Exec Hy Levitsky
“Cancer immunology will play a far greater role than it ever has within the [Roche Pharma Research and Early Development Organization] and we hope there will be synergies we can exploit with other treatment modalities under development at Roche,” Levitsky says.
With Strong Safety Data For LibiGel, BioSante Raises $11.1 Million
Down to about $6 million at the end of the second quarter, the sexual health products firm uses a merger and private placement to significantly upgrade its cash position.
With Strong Safety Data For LibiGel, BioSante Raises $11.1 Million
Down to about $6 million at the end of the second quarter, the sexual health products firm uses a merger and private placement to significantly upgrade its cash position.